PF03715455

• Catalog Number: orb746383
• Category: Small Molecules
• Description: PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC50 values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease)[1][2].PF-03715455 is a moderate inhibitor of CYP1A2, CYP2C19, and CYP2D6 and a potent inhibitor of CYP’s 2C9 and CYP3A4[2].PF-03715455 treatment shows that the Vss and T1/2 are 0.19 L/kg, 1 hour, respectively[2]. Animal Model: Male CD Sprague Dawley rats (300-450 g)[2] Dosage: 1 mg/kg Administration: I.v. (Pharmacokinetic Analysis) Result: The Vss, and T1/2 were 0.19 L/kg, 1 hour, respectively.
• CAS Number: [1056164-52-3]
• MW: 700.27
• SMILES: O=C(NC1N(C2C=C(Cl)C(O)=CC=2)N=C(C(C)(C)C)C=1)NCC1C(SC2C=CC3=NN=C(C4C(SCCO)=CC=CC=4)N3C=2)=CC=CC=1
• Formula: C₃₅H₃₄ClN₇O₃S₂
• Note: For research use only
• Expiration Date: 12 months from date of receipt.